Online medisch consult voor Tirzepatide.

Tirzepatide is the same molecule sold as Mounjaro (type-2 diabetes) and Zepbound (weight management). Unlike pure GLP-1 analogues, it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor — a second incretin pathway involved in appetite regulation and insulin sensitivity.

That dual activity is what sets tirzepatide apart from semaglutide in head-to-head trials: average weight loss in phase-III studies is somewhat larger, though eligibility criteria and the side-effect profile are similar.

The combined activation of GIP and GLP-1 receptors produces synergistic effects:

• Central appetite reduction (hypothalamus).
• Improved insulin sensitivity and post-prandial glucose handling.
• Slower gastric emptying, comparable to pure GLP-1 analogues.
• Documented lipid-metabolism modulation in trials.

The doctor decides whether the dual activity fits your clinical profile — it is not first-line for every patient and the choice between tirzepatide and semaglutide is always medical, never commercial.

Adults with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type-2 diabetes, dyslipidaemia, sleep apnoea).

Contraindications mirror GLP-1s: history of medullary thyroid carcinoma, MEN-2, prior pancreatitis, pregnancy, breastfeeding. Management is medical and reviewed case by case.

Dosing starts low and escalates every four weeks up to the maintenance dose set by the doctor. The first weeks concentrate gastrointestinal effects — most resolve with schedule adjustments.

Weight changes are measurable from the second or third month; trials document average losses of 15–20 % of starting weight sustained at 18 months with medical follow-up and habit changes.

Common adverse events are nausea, diarrhoea, vomiting and constipation, especially during dose escalation. Most are mild; the doctor slows the schedule if they interfere.

Periodic clinical follow-up is required — weight, blood pressure, blood glucose where applicable — all inside the private chat in your account. The medication continues as long as the doctor considers the benefit/risk balance favourable.